Semaglutide is the compound everything else in this category gets measured against. Our Tirzepatide vs. Semaglutide and Mazdutide vs. Tirzepatide articles both reference it as the benchmark. And yet it’s never had its own dedicated deep-dive here — which is a genuine gap, because semaglutide is, by a wide margin, the single most extensively trialed compound covered anywhere on this site, with human data spanning weight loss, heart disease, kidney health, and heart failure.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist — a lab-made version of a hormone your gut releases naturally after you eat. It was originally developed and approved for type 2 diabetes (sold as Ozempic and Rybelsus) before getting a separate approval for chronic weight management under the name Wegovy. Mechanically, it slows down digestion, tells your liver to stop overproducing sugar, nudges your pancreas to release insulin only when blood sugar is actually high, and quiets the appetite signals in your brain.
What actually sets semaglutide apart from nearly everything else discussed on this site isn’t the mechanism — plenty of GLP-1 drugs work similarly. It’s the sheer size and rigor of the human trial program behind it, which is worth walking through trial by trial rather than treating as one big blob of “semaglutide research.”
The STEP Trials: Proving Semaglutide Actually Works for Weight Loss
The STEP program is the foundational efficacy series, and a few individual trials inside it are worth calling out separately.
STEP 1 is the trial that established the core weight-loss effect in adults with obesity or overweight who didn’t have diabetes — and it’s the data that got Wegovy approved in the first place.
STEP 4 asked a different, more practical question: what happens after the weight comes off? It tested whether people who kept taking weekly semaglutide maintained their results better than people switched to placebo after an initial period on the drug. They did — significantly better. And a related extension of STEP 1 found that people who stopped the drug regained weight and lost the metabolic improvements they’d gained. That’s one of the more important findings in the whole semaglutide story: the effects don’t stick around on their own once you stop. This is an ongoing treatment, not a one-time fix.
STEP UP tested whether a higher 7.2 mg dose beat the standard 2.4 mg dose. Starting from an average baseline weight of 113 kg, the higher dose produced 20.7% weight loss at 72 weeks, versus 17.5% on the standard dose and just 2.4% on placebo — and a third of the high-dose group lost a quarter of their body weight or more, roughly double the rate on the standard dose. Crucially, Novo Nordisk reported the safety and tolerability profile of the higher dose as comparable to the standard one. A dose-response benefit that came bundled with proportionally worse side effects would tell a very different story — this one doesn’t.
STEP-HFpEF and STEP-HFpEF DM pushed the trial program into a specific, historically underserved group: people with a type of heart failure called HFpEF, which has had frustratingly few effective treatments over the years. At one year, semaglutide didn’t just produce substantial weight loss in this group — it meaningfully improved quality of life, physical function, and how far people could walk in six minutes. Those are outcomes that matter on their own, independent of anything the scale says.
SELECT: The Trial That Changed the Whole Conversation
If STEP proved semaglutide causes weight loss, SELECT is arguably the more important trial, because it tested something entirely different: heart disease outcomes, not weight, as the actual thing being measured.
SELECT enrolled 17,604 adults with existing heart disease and overweight or obesity — deliberately leaving out people with diabetes, specifically so the cardiovascular results couldn’t be explained away as a diabetes effect. The headline finding: semaglutide cut major cardiovascular events — heart attack, stroke, cardiovascular death — by 20% compared to placebo. That result led directly to a March 2024 FDA approval specifically for reducing cardiovascular risk in people with existing heart disease and obesity or overweight, a distinct approval from the original weight-loss indication.
A series of follow-up analyses from SELECT add real nuance here, and they’re worth knowing individually:
- The weight loss held up over years, not just months. Tracking participants out to roughly four years found sustained weight loss of 10.2% versus 1.5% on placebo, consistent across sexes, races, body sizes, and regions around the world.
- The heart benefit didn’t just track with how much weight someone lost. This is genuinely the most interesting finding in the whole dataset. Researchers specifically checked whether the cardiovascular benefit was proportional to weight loss, and it wasn’t — people benefited even when their weight loss was modest. That suggests semaglutide might be doing something for the heart directly, not just indirectly through weight loss, which has led some researchers to argue GLP-1 drugs should be thought of as heart-disease treatments in their own right, not weight-loss drugs with a nice side effect.
- Kidney health improved too. A composite measure of kidney problems — dialysis, kidney-related death, major function decline — happened less often on semaglutide (1.8%) than placebo (2.2%), with the biggest benefit showing up in people who already had reduced kidney function going in.
- People with existing heart failure benefited specifically. A subgroup analysis within SELECT found reduced cardiovascular events and heart-failure-specific outcomes in participants who already had heart failure, regardless of which type — relevant given how much more common heart failure is among people with obesity in the first place.
What’s Still Genuinely Unclear
Even with all this data, a few real questions remain open. Trial populations aren’t the same as everyone actually using the drug today — SELECT specifically enrolled people who already had heart disease, so its cardiovascular findings don’t automatically apply to someone with obesity but no diagnosed heart condition. Long-term data keeps accumulating, but multi-decade outcomes simply don’t exist yet for a drug whose high-dose weight-management version is still fairly recent. And the mechanism behind that surprising finding — cardiovascular benefit that doesn’t scale with weight loss — is still being actively investigated, not settled science. There’s also the practical question of access and cost, which shapes real-world use in ways a clinical trial, where medication is provided free to participants, simply doesn’t capture.
Quick Questions
Is semaglutide the same thing whether it’s called Ozempic, Wegovy, or Rybelsus?
Same active compound — the products differ in approved use, dose, and form. Rybelsus is a pill; Ozempic and Wegovy are injections, with Wegovy carrying the higher dose and the weight-management and cardiovascular-risk approvals covered above.
Does it work the same for everyone?
The SELECT weight-loss data specifically found consistent benefit across sexes, races, body sizes, and geographic regions — a genuinely broad result — though individual response naturally varies from person to person, as with any medication.
What happens if you stop taking it?
Based on the STEP 4 and STEP 1 extension data, stopping leads to weight regain and a reversal of the metabolic gains made during treatment. That’s consistent with thinking of semaglutide as ongoing management for a chronic condition, not a finite course of treatment with effects that last on their own.
What are the most common side effects, based on the trials?
Across the STEP and SELECT programs, the side effects reported most often were gastrointestinal — nausea, vomiting, diarrhea — particularly during dose increases, which is consistent with how the drug works by slowing digestion. This is a real and common experience for a lot of people on the drug, not a rare edge case, even though the trials describe most of it as mild to moderate and often improving over time.
For more on how semaglutide compares to compounds still earlier in their development — including some that work through mechanistically similar but structurally different approaches — our Tirzepatide vs. Semaglutide and Retatrutide dosage articles are a natural next read, and our Are Peptides Safe for Weight Loss piece covers the broader safety landscape across this whole category.
Bottom Line
Semaglutide’s clinical trial program is the most extensive and rigorous body of evidence behind any compound covered on this site — spanning weight loss, cardiovascular risk, kidney health, and heart failure, with findings that look like genuinely separate mechanisms rather than one effect measured five different ways. It’s also clear that the benefits depend on staying on the drug, and that — like any medication — the trial data reflects the specific populations and timeframes actually studied, which is worth remembering as its real-world use keeps expanding well past the original trial populations. If there’s one thing that sets semaglutide apart from almost everything else on this site, it’s simply this: the evidence here doesn’t ask you to take much on faith.
This is educational content based on published clinical trial data and is not medical advice. Semaglutide is an FDA-approved prescription medication; decisions about its use belong with a licensed healthcare provider, not with this article.